Tumor Genetics and Immune Profiling Guide Personalized Lung Cancer Immunotherapy
A review in Genes & Diseases highlights how evaluating tumor genetics alongside the surrounding immune microenvironment can refine immunotherapy selection ...
A review in Genes & Diseases highlights how evaluating tumor genetics alongside the surrounding immune microenvironment can refine immunotherapy selection ...
Decitabine helps resensitize drug-resistant non-small cell lung cancer cells to osimertinib by reducing TP53INP1 promoter methylation and engaging autophagy.
A comprehensive review analyzes emerging liquid biopsy, epigenetic, and radiomic biomarkers designed to enhance the accuracy and non-invasive detection of ...
A comprehensive review examines circulating tumor DNA across solid tumors, highlighting its prognostic accuracy in minimal residual disease alongside key ...
A new clinical guide in Frontiers in Oncology outlines an integrated care pathway for young-onset lung cancer, emphasizing urgent genomic ...
A clinical trial evaluating a triple combination therapy in EGFR-mutant lung cancer found that TP53 and RB1 mutations drive treatment ...
A decision-tree simulation shows that pathologist-initiated reflex testing for non-small cell lung cancer improves survival while lowering annual healthcare expenditures ...
A retrospective study of 1,515 patients indicates that genetic testing and targeted therapy enhance clinical outcomes and reduce healthcare costs ...
A retrospective study of seventy-two lung adenocarcinoma patients indicates that quantitative spectral parameters from photon-counting computed tomography can noninvasively assist ...
A case report describes rare germline MUC16 variants shared by four siblings with multiple primary lung adenocarcinomas, suggesting possible familial ...
A retrospective single-center analysis of 452 Chinese patients with non-small cell lung cancer associated compound and co-occurring EGFR mutations with ...
A retrospective study of 154 patients links adjuvant EGFR inhibitors with longer three-year disease-free survival after surgery for non-small cell ...
A six-center retrospective study of 275 osimertinib-treated patients associated postoperative recurrence with longer progression-free and overall survival than de novo ...
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
In the ever-evolving landscape of cancer treatment, recent breakthroughs in the fight against non-small cell lung cancer (NSCLC) have brought ...
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) ...
The latest advancements in cancer treatment are offering new hope to patients with advanced non-small cell lung cancer (NSCLC), especially ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.